Telix Pharmaceuticals (NASDAQ:TLX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Telix Pharmaceuticals (NASDAQ:TLX) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other brokerages have also weighed in on TLX. Royal Bank Of Canada started coverage on Telix Pharmaceuticals in a research note on Monday, December 15th. They set a “hold” rating on the stock. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. HC Wainwright lowered their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Finally, Citigroup initiated coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Price Performance

Shares of TLX opened at $7.80 on Friday. Telix Pharmaceuticals has a 1 year low of $7.72 and a 1 year high of $30.36. The company’s 50 day simple moving average is $9.79 and its 200 day simple moving average is $11.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers increased its position in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares in the last quarter. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $213,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals in the second quarter valued at about $217,000. JPMorgan Chase & Co. acquired a new position in shares of Telix Pharmaceuticals during the third quarter worth about $243,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth about $297,000.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Advancement of TLX591 into ProstACT Global Phase 3 Part 2 — a clinical development milestone that supports the company’s long-term commercial case for its prostate cancer program. Telix valuation/clinical update
• Neutral Sentiment: Recent analyst coverage is cautious: RBC initiated coverage with a Sector Perform rating and a price target that implies upside vs current U.S. quotes, but the note emphasizes a cautious commercial outlook and execution risk. InsiderMonkey summary
• Negative Sentiment: Hagens Berman highlights serious allegations including an SEC subpoena and an FDA complete response letter (CRL) focused on CMC/supply?chain and third?party manufacturing deficiencies tied to TLX591, and urges investors to act by Jan. 9 — these specific regulatory and oversight claims raise material execution and disclosure risk. Hagens Berman PR
• Negative Sentiment: Multiple shareholder?rights firms (Berger Montague, Faruqi & Faruqi, Levi & Korsinsky, Rosen, The Gross Law Firm, Schall, et al.) have filed or circulated class?action notices and reminders relating to securities purchased Feb. 21–Aug. 28, 2025 and the Jan. 9 lead?plaintiff deadline — the wave of litigation notices increases headline risk, potential litigation costs and market volatility. Berger Montague notice

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.